- Boehringer Ingelheim grants a total prize of 15,000 euros to the top 10 clinical cases
- Boehringer Ingelheim encourages the search for both clinical and subclinical cases of bovine viral diarrhea (BVD) in cattle herds, aiming to improve BVD awareness
Boehringer Ingelheim has announced the winners of the 2018 “BVDzero Case Awards”. These awards reflect Boehringer Ingelheim’s long-term commitment to promoting health and well-being of farm animals.
“Bovine viral diarrhea virus (BVDV) is one of the most common diseases in cattle, causing harm to the affected animals and huge economic damage to the livestock industry. We aim to challenge the status quo and bring a paradigm shift in the control of BVD,” commented Steve Williams, Head of Global Ruminants/Cattle Strategic Business Unit at Boehringer Ingelheim.
This year’s BVDzero Press Conference and Award ceremony took place in Barcelona, Spain on 23 October 2018. The award winners have been selected by the BVDzero Committee, consisting of renowned external experts in the field of bovine health.
Boehringer Ingelheim provided a total prize of 15,000 euros for the top 10 clinical cases entered. These cases included submissions from Italy, Spain, the Netherlands, the UK, Brazil and Turkey.
The authors of the top three winning cases, Anna Bruguera Sala (UK), Danilo Ghilardi (Italy) and Colin Buchan (UK), presented their submissions during the press conference. They accepted their prizes from Volker Moennig, Head of the BVDzero Committee.
The guests also had the opportunity to hear two more speakers: Mike Kerby BVSc DBR MRCVS, Delaware Veterinary Group, who gave a speech titled A UK Practitioner’s Experience with BVD Control, and Lucy Metcalfe, Boehringer Ingelheim’s Global Technical Manager for Ruminants, provided a global update on BVD prevalence and control.
Through the “BVDzero Case Awards”, Boehringer Ingelheim aims to keep encouraging the search for both clinical and subclinical cases of BVD in cattle herds. The company believes that such events will help increase BVD awareness and, as a result, help reduce its prevalence.
The Boehringer Ingelheim BVDzero team plans to continue this initiative in the future.